Lexicon Data Shows Sotagliflozin Benefits Broad Patient Groups

Event summary

  • Lexicon Pharmaceuticals presented data from Phase 3 SCORED study demonstrating sotagliflozin reduced heart failure and major adverse cardiovascular events (MACE) across BMI strata.
  • SOTA-P-CARDIA trial data showed sotagliflozin improved health-related quality of life and physical limitation in HFpEF patients without diabetes.
  • The SOTA-P-CARDIA study also indicated a potential reduction in epicardial adipose tissue with sotagliflozin.
  • Presentations occurred at the American College of Cardiology (ACC) Annual Scientific Session & Expo, March 28-30, 2026.

The big picture

Lexicon's sotagliflozin data reinforces the growing trend of dual SGLT1/SGLT2 inhibitors in cardiovascular disease management. The findings across diverse patient populations, including those without diabetes, broaden the potential market for the drug and suggest a pathway for addressing unmet needs in HFpEF. This strengthens Lexicon's position in a competitive market, but success hinges on regulatory acceptance and physician adoption.

What we're watching

Clinical Adoption
The speed of clinical adoption will depend on how these findings are interpreted by clinicians and incorporated into treatment guidelines, potentially impacting sotagliflozin’s market penetration.
Mechanistic Pathway
Further investigation into the potential reduction of epicardial adipose tissue could reveal novel therapeutic applications and strengthen sotagliflozin’s intellectual property position.
Regulatory Approval
The FDA’s assessment of these data, particularly the BMI stratification findings, will influence the labeling and potential expansion of sotagliflozin’s approved indications.

Related topics

Pharmaceuticals